UMN Pharma Inc (4585.T) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UMN Pharma Inc amends consolidated mid-year outlook for FY 2014


Tuesday, 22 Jul 2014 04:25am EDT 

UMN Pharma Inc:Says the company lowered the consolidated mid-year outlook for revenue to 1,078 million yen from 1,105 million yen for FY ending Dec. 2014.Operating profit forecast increased to a loss of 1,796 million yen from a loss of 2,167 million yen.Ordinary profit forecast increased to a loss of 1,967 million yen from a loss of 2,292 million yen.Net profit forecast increased to a loss of 1,677 million yen from a loss of 2,079 million yen.Earnings per share increased to a loss of 198.63 yen from a loss of 246.74 yen.Comments the decreased research and development fund is the main reason for the forecast. 

Company Quote

1406.0
-28.0 -1.95%
27 Jun 2016